CAR-T Cell Therapy for Advanced Solid Tumors
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target two markers on cancer cells at once. The goal is to help patients with advanced solid tumors where standard treatments have stopped working or aren't an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have advanced cancer (solid tumor) that has spread, come back, or cannot be removed by surgery, and standard treatments have failed or aren't suitable for you
- Your tumor shows two specific markers (proteins) when tested by the study team, with the primary marker present in at least 50% of cancer cells
- You have measurable disease on imaging scans (CT, MRI, or other standard scans)
- Your overall health is good enough for this treatment (ECOG score 0–1, or 0–2 for brain tumors if approved)
- Your blood cell counts, kidney and liver function, heart function, and oxygen levels meet minimum safe requirements
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy called CAR-T cells that are designed to find and attack cancer cells that have a specific marker (GD2 or PSMA). It is for people whose cancer has not been controlled by standard treatment, and it aims to see if this therapy is safe and effective.
This trial is testing a new CAR-T cell therapy given as an injection for people with advanced or metastatic solid tumors that have stopped responding to standard treatments. CAR-T therapy uses your own immune cells to target and attack cancer cells. It may be an option if you have tried other treatments and they are no longer working.
This trial tests a new type of immune cell therapy (CAR-T) that targets specific proteins (CD73 and AXL) on tumor cells. It is for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this therapy can shrink tumors or slow their growth.
This Phase 1/2 trial tests a lab-made immune therapy (CAR-T) designed to attack cancers that have a protein called CD70. It may help people whose solid tumor has not responded to standard treatment, but it also requires specific lab confirmation and careful health screening.
This trial tests a new type of cell therapy (CAR-T and targeted DC cells) for people with advanced solid tumors that have specific proteins. It aims to see if these immune cells can shrink tumors or slow their growth.
This trial tests a lab-made immune therapy (CAR-T) that targets a protein called CD70 found on some advanced cancers. It’s designed for people whose solid tumors have spread and no standard treatments have worked or weren’t tolerated.
Hear when a new Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.